Search

Your search keyword '"G. Schardt"' showing total 2 results
Start Over Author "G. Schardt" Publisher informa uk limited
2 results on '"G. Schardt"'

1. ESC/EAS clinical guidance recommendations: impact on patient eligibility for PCSK9 inhibitor therapy

Author

K. Nolan, M. Wolfe, J. Murray, D. Hilleman, and G. Schardt

Subjects
Oncology, medicine.medical_specialty, animal structures, business.industry, PCSK9, Internal medicine, fungi, medicine, Subtilisin, Kexin, Proprotein convertase, business
Abstract

Background: The proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors have been demonstrated to significantly reduce the risk of recurrent adverse vascular events in high-risk patients w...

Published
2018
Full Text
View/download PDF

2. Impact of a dedicated medication access coordinator on PCSK9 inhibitor approval rates

Author

M. Wolfe, D. Hilleman, G. Schardt, and K. Nolan

Subjects
medicine.medical_specialty, animal structures, High risk patients, business.industry, Internal medicine, PCSK9, fungi, medicine, Subtilisin, Kexin, Prior authorization, business, Proprotein convertase
Abstract

Background: The proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors significantly reduce the risk of major adverse cardiovascular events in high risk patients. The most significant bar...

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results